Global CHC Market Movers, MAT Q1 2021

We have now published our latest Market Movers update on the CHC Dashboard website, highlighting 6 brands that have been driving growth in the global CHC market in the MAT Q1 2021 period, as well as 6 brands in fast decline, and below we look at the trends behind these exceptional brand performances.

Given that antiseptics & disinfectants were by far the biggest growth driver in the global CHC market in MAT Q1 2021, it’s no surprise that two of the six fastest-growing brands were hand sanitisers, Unilever’s Suave and ArtNaturals (ArtNaturals). Both were standout performers in the US market among a raft of new entries in the vibrant subcategory.

Rx-to-OTC switch has also been an important growth driver, with GSK’s May 2020 launch of topical analgesic Voltaren Arthritis Pain the notable development, generating sales in excess of US$100mn in under a year on the market. Former switch brand Plan B One-Step also performed exceptionally well in MAT Q1 2021, owing to limited access to prescribed contraception and family planning clinics during the pandemic. Foundation Consumer Healthcare also backed the brand with TV ads explaining it does not affect future fertility.

In China, the two fastest-growing CHC brands were Mayinglong Musk, a haemorrhoid preparation extended into new subcategories thanks to product innovation, and Fu Fang E Jiao Jiang, which marketer Dong-e E-jiao Group revived by returning to a policy of targeting general (not just high-end) consumers, helping ensure a return to growth overall for tonics & cure alls in China.

As for products that suffered falling sales in MAT Q1 2021, the clear majority (4 out of 6) were CCA brands, given the historically weak cough & cold season experienced by the industry in the first quarter of this year. Global No.1 brand Vicks posted further heavy decline in Q1, with MAT Q1 2021 sales falling by 24.5%; combo packs of Vicks NyQuil / DayQuil packs fell particularly hard (-54%).

Reckitt’s systemic cold & flu treatment Mucinex Fast-Max and cough remedy Delsym also suffered heavy decline in MAT Q1 2021, as did Taisho’s cold remedy Pabron in Japan, which was hit by the downturn for domestic and inbound channels attributable to Covid-related issues.

We are pleased to announce that Nicholas Hall’s North American e-Conference 2021 will take place on 21 September! Sponsored by Catalent, Nicholas will be joined by industry experts to explore Challenger Brands & Key Pillars to the New / Modern Marketing World. To register, or to find out more, please contact elizabeth.bernos@NicholasHall.com.

CVS Study: Consumers taking better control of health

CVS Health’s just-published 2021 Health Care Insights Study, which asked 1,000 consumers and 400 providers for their thoughts on the state of healthcare and how they are navigating this evolving landscape, reveals preferences for a more personalised, customisable and accessible experience.

Even as access to health insurance coverage (55%) and location of care (43%) remain among the top factors that influence consumer healthcare decisions, more people are exploring different avenues of care, with a slight movement away from primary care providers (PCPs) to other healthcare resources. Routine care from PCPs has dropped since last year (56% vs 62%), while the use of online resources (19% vs 12%), community health centres (19% vs 15%) and local pharmacies (17% vs 11%) have grown in preference.

Other findings include:

  • 77% said the pandemic has led them to pay more attention to their health in general, while 50% indicated previous stay-at-home orders helped them achieve their health goals
  • In addition to increased substance use, feelings of stress have been pervasive, especially for men, who reported slightly higher levels of stress vs female respondents over the significant shifts that took place during quarantine
  • Young adults (18-34 years) were most impacted by the pandemic and the most likely age group to report depression (35%) and a higher rate of mental illness (28%) vs total respondents (23%)

Comment from CVS Health President & CEO, Karen Lynch: Over the past year-and-a-half, we have witnessed a dramatic shift in consumer healthcare preferences and needs. These shifts towards personalised care have the potential to impact our healthcare system well past the pandemic, with many people taking a more engaged approach to their own health. Going forward, we have an opportunity to take what we’ve learned and continue to foster an integrated health model that is centred around the needs of the individual.

Will consumer interest in boosting immunity outlast Covid? Is the shift to prevention products sustainable? These important questions will be explored in our forthcoming hot topic report focusing on Immunity. A number of categories including antivirals, immune supplements and vitamins C & D will be featured, alongside the latest launch activity and much more. To pre-order your copy and save with the pre-publication discount, or to find out more, please contact Melissa.Lee@NicholasHall.com.

MAT Q1 2021: Global CHC sales fall 0.6%

According to Nicholas Hall’s global sales database DB6, the retail (bricks & mortar) CHC market generated global sales of US$148bn, down by -0.6% versus a year ago. Further heavy decline for cough, cold & allergy (-14.5%), especially in North America and Western Europe, was largely responsible for the global fall in CHC sales. The Americas declined by -0.4%, driven by a -1.9% fall in North America, but slightly offset by a positive performance by LatAm markets (+8.5%), notably double-digit growth in Brazil (+10.6%).

Asia remained relatively weak (+2.6%); despite strong growth in China (+7.1%), the region continues to be impacted by loss of revenue from overseas visitors in key markets Japan (-9.1%) and Australia (-8.0%). Europe saw a significant downturn (-5.5%), heavily impacted by declines in CCA and analgesics in Western Europe. Key markets Germany (-13.3%) and UK (-13.9%) fell by double-digits during the MAT Q1 2021 period. In C&E Europe, meanwhile, Russia continued to post a positive performance (+4.1%), albeit at a slower rate than year-end.

As for global performance by major category, vitamins, minerals & supplements (+5.3%) remained the fastest-growing category – albeit at a slower rate than year-end 2020 – with immune-associated categories continuing to benefit from greater consumer focus on wellness maintenance and protection. Dermatologicals increased by +4.5%, its buoyancy largely attributed to the performance of antiseptics & disinfectants (+53.1%) during the pandemic. Lifestyle CHC grew by +2.4%, driven by double-digit increases in sedatives & sleep aids (+14.5%) as well as smaller categories such as obesity treatments, emergency hormonal contraception and erectile dysfunction.

Gastrointestinals returned a low level increase (+1.2%), while analgesics saw a decline of -1.8% globally, with systemics down -4.3%, largely owing to the effects of pantry loading at the start of the pandemic. Cough, cold & allergy saw the strongest decline, with sales falling by -14.5% in the 12 months to end March. Pantry loading, as well as the effects of lockdown restrictions, social distancing, mask wearing and hygiene measures resulted in significantly reduced incidence of respiratory pathologies.

At a time when consumers are highly aware of the importance of maintaining their immune system, we are pleased to announce that Immunity will be the focus of our next hot topic report! We will review a number of categories including antivirals, immune supplements and vitamins C & D and explore the latest launch activity, plus much more. To pre-order your copy and save with the pre-publication discount, or to find out more, please contact Melissa.Lee@NicholasHall.com.

Seasonal respiratory viruses re-emerge post-Covid

Recent reports from the UK and USA suggest a severe cold & flu season may be in store during winter 2021-22. With lockdown restrictions, increased hygiene measures and social distancing in force for over a year to reduce the risk of contracting Covid-19, the incidence of common respiratory viruses has been very low. However, with the lack of exposure to illnesses (especially among young children), many of us have not built up antibodies and as a result our immune systems may have been inadvertently weakened.

This has prompted warnings of a potential surge in influenza as measures are lifted; data released this week by the UK’s Office of National Statistics show that in the week ending 11th June, 84 death certificates issued in England & Wales mentioned Covid, while 1,163 deaths involving flu and pneumonia were registered. Additionally, a recent study by the Houston Methodist Research Institute shows the rapid re-emergence of seasonal respiratory viruses following the relaxing of Covid-19 restrictions in Texas in March 2021.

This trend was also reported in a recent article in STAT, in which Trevor Bedford, a computational biologist who monitors which viruses are circulating via the Nextstrain service, was quoted as saying: “Just in the last month [May 2021] or so we’ve started to pick up small amounts of seasonal coronavirus, RSV, metapneumovirus, etc. It’s the first time since April 2020 where we’re starting to see other things circulating.”

There is particular concern that by the time universities, colleges, schools and nurseries reopen this autumn across the northern hemisphere, there will be perfect conditions for high transmission of seasonal respiratory viruses, particularly RSV (respiratory syncytial virus). Andrew Pavia, Chief of the Division of Pediatric Infectious Diseases at the University of Utah, warned: “There will be two years’ worth of kids who are naïve to RSV, instead of one birth cohort. That could be fertile ground for a big RSV year.”

Epidemiologist Professor Neil Ferguson of Imperial College, a member of the UK Government’s Scientific Advisory Group for Emergencies, said in a BBC interview that we must be prepared for a potentially “quite significant” flu epidemic and increased hospitalisations this winter. To help save National Health Service resources, researchers are investigating whether seasonal flu jabs and a Covid vaccine can be administered at the same time.

We are pleased to announce that our Eye Health report is now published and available to order! You can review case studies of key brands, NPD activity and much more. Plus, ensure you have registered for the free webinar on 30 June here to discuss the topline findings. For more information, please contact melissa.lee@NicholasHall.com.

Stada Health Report 2021

According to the third Stada Health Report, a representative survey of 30,000 participants in 15 European countries, 29% have suffered from increased levels of anxiety during the pandemic, while 25% are troubled by stress and inner restlessness and 15% have reported sleep disturbances. Some 52% of respondents are more affected by the lack of personal contact with family & friends than fear of Covid infection (42%), while almost 1 in 3 worries about the financial and work-related repercussions.

However, 70% of Europeans have been willing to invest more in their own health. For 73%, their doctor is the first point of call for all health-related issues, with pharmacists and scientists also highly trusted (60% each). Despite a 14 percentage-point increase in people purchasing medication online, 43% stay loyal to community pharmacies, 13% of which specifically single out their local branch. Europeans care more about brand names and what is associated with them (38%) rather than sustainable & environmentally-friendly packaging (25%) or whether a product was made in Europe (20%).

In the report, Stada asks the question, “With an increased interest in and an aspiration to healthy living, how did people in Europe procure information on these topics? The short answer is: The internet. 54% of Europeans have increased their online searches for health-related information compared to previous years.” However, this spike in online health searches and literacy has not automatically translated into European consumers looking to bypass their pharmacist when acquiring medication, or information about it. According to Stada’s survey, only 14% of Europeans have ordered more OTC medicines via online pharmacies post-pandemic, and 43% flat out refuse to order them online at all. Despite the ever increasing number of e-Commerce platforms and other channels for obtaining medicines online, community pharmacies are still Europe’s first choice for OTCs.

Nicholas Hall’s Touchpoints: The Stada report quoted above is further evidence that increased levels of stress and anxiety, and disrupted sleep, are by-products of Covid. Insomnia was already considered a pandemic in the Western world by the World Health Organization; and sleep, stress and mood have joined immunity and disinfection as categories with rocketing sales in the past two years … The theme continues in the latest Gallup survey, which notes the high incidence of “worry, stress, anger and sadness among employees worldwide”. It seems that substantial numbers of office workers are refusing to go back to work in the traditional way and are insisting on continuing to work from home … This localisation of labour will almost certainly change our concept of shopping and could benefit independent neighbourhood pharmacies, giving a whole new meaning to the concept of Pharmacy Point-of-Care. It’s too soon to draw definite conclusions, but consumer healthcare companies would do well to re-examine their sales force objectives. One of the most successful modules of the CHC Training Academy is “Winning in Pharmacy”, and I can see this being even more popular as we come out of the Covid lockdown.

To find out more about Winning in Pharmacy, or the offerings from The CHC Training Academy, please contact maricar.montero@NicholasHall.com. The CHC Training Academy can also work with you to develop your own in-house customised training programmes according to your specific strategic needs.

AESGP 57th Annual Meeting Review

From CHC Insight Europe Editor, Sarah Carter, who reports that the AESGP sees a brilliant future for self-care, but that the industry must continue to adapt.

Focusing on self-care in times of the pandemic and beyond, the 57th AESGP Annual Meeting discussed opportunities, challenges and lessons learnt. While the pandemic has caused significant disruption and altered behaviours, priorities and shopping habits, it has driven a surge in interest in self-care, with consumers increasingly looking to stay well and prevent illness. Birgit Schuhbauer, who has just been re-elected as AESGP President for the next two years, stated that the CHC industry has a “brilliant future ahead of us”.

The CHC industry has had to adapt to this changing landscape, although a number of speakers stressed that it must do so at a quicker pace as technology and evolving consumer demands continue to disrupt the traditional self-care model. AESGP Director General Jurate Svarcaite concluded that there is no going back to the old model, stressing that the “new normal” requires collaboration and partnership.

Speakers also touched upon the infodemic and the increasing consumer appetite for instant information, which European Medicines Agency Executive Director Emer Cooke said was difficult to manage when you try to have a “sound scientific basis for what you communicate”. However, the worrying spread of misinformation and disinformation means that increased and better communication is vital.

The Annual Meeting coincided with the long-awaited implementation of the new EU Medical Device Regulation; participants shared their excitement and optimism at the development and celebrated how much work had been done, but were keen to stress there remains a way to go, particularly in terms of harmonisation across Europe and the capacity of notified bodies.

There is still time to register for our free webinar on 30 June discussing the topline conclusions from our upcoming report on Eye Health! With no purchase necessary, you can register directly for the webinar here. For more information, please contact melissa.lee@NicholasHall.com.

Rx-to-OTC switch drivers

Allergy and sexual health are two areas of the global CHC market that continue to expand in sales thanks to Rx to non-prescription switch activity in various markets. In Japan, the Ministry of Health, Labour & Welfare’s Evaluation (MHLW) Review Conference will discuss the potential Rx-to-OTC switch of emergency hormonal contraceptives at a meeting this week.

According to CHC Insight Asia-Pacific Senior Editor, Nicola Allan: “In June 2019, an MHLW steering committee permitted pharmacists to dispense EHCs during a face-to-face transaction after the consumer has had an online consultation with a doctor. Previously, the patient had to see a doctor face-to-face to obtain a prescription to give to the pharmacist. More than 9,000 pharmacists have undertaken training that allows them to participate in the new scheme, which has prompted the MHLW to consider further liberalisation of EHC sales.”

Meanwhile, in the UK, following an application from Sanofi, the Medicines & Healthcare products Regulatory Agency last week reclassified Nasacort Allergy Relief (triamcinolone acetonide 55mcg / dose) nasal spray from Pharmacy medicine to General Sales List. The suspension can be used for the relief of symptoms associated with seasonal allergic rhinitis, including sneezing, itchy and runny nose, itchy red or watery eyes, nasal congestion or sinus discomfort in adults aged 18+ years.

In terms of switch drivers, governments seeking to reduce healthcare costs remains a primary factor, but also important is the empowerment of consumers as they increasingly use digital solutions to improve and monitor their health, a trend that is being leveraged into test & treat models. Commenting on the just-published Rx-to-OTC Switch Hot Topic Report, CIMA Senior Market Analyst Victoria Blake said the report “considers the impact of Covid on struggling healthcare systems, and the increased burden on the undertreated population. While traditional mechanisms have proved too slow in recent years, the next generation of switches – such as statins, triptans, oral contraceptives and CBD – require new thinking and a different approach.”

According to Nicholas Hall, “we could be entering a Golden Age. Voltaren Arthritis Pain Relief Gel’s successful US launch; OTC approval for low-dose cannabis in Australia; the possibility of OTC oral contraceptives in a major Western market for the first time; plus recent statements by Sanofi on the likely switches of the antiviral Tamiflu and the erectile dysfunction treatment Cialis. These are just the tonic this industry needs as the recovery from Covid gets underway.”

Our hot topic report Rx-to-OTC Switch is now published! Written by Nicholas Hall’s CIMA team in association with switch expert Joe McGovern of Biograph Inc, you can access information on the historic and current switch environments in key global markets, including an overview of pipeline and strategic considerations. For more information, or to purchase your copy, please contact melissa.lee@NicholasHall.com

Google’s Derm Assist AI tool

Google is making a big move into healthcare with its announcement last week of a new AI skin care tool, Derm Assist, which is set to launch in Europe later this year. The new tool received a Class I medical device CE mark from European regulators, and is backed by landmark research that was published in Nature Medicine this time last year, showing how Google’s AI model was trained on more than 16,000 real-world dermatology cases and achieved accuracy on a par with US board-certified dermatologists. Another more recent study in JAMA Network indicated the AI tool also significantly improved diagnostic accuracy of non-derma specialists such as GPs.

In its blog announcement, Google said: “With our CE marked AI-powered dermatology assist tool, a web-based application that we aim to make available for early testing in the EU later this year, it’s easier to figure out what might be going on with your skin. Simply use your phone’s camera to take three images of the skin, hair or nail concern from different angles. You’ll then be asked questions about your skin type, how long you’ve had the issue and other symptoms that help the AI to narrow down the possibilities. The AI model analyses all of this information and draws from its knowledge of 288 conditions to give you a list of possible conditions that you can then research further. It’s not meant to be a replacement for diagnosis, but rather a good place to start.”

Google said that it sees billions of Google Searches every year related to skin, nail and hair issues, but that it remains difficult for people to describe what they see on their skin through words alone. According to the FT, Google cited studies showing that people only diagnose themselves correctly 13% of the time when it comes to skin conditions, presenting a huge opportunity for the Derm Assist tool. In the blog announcement, Google provided a visual walkthrough of how the tool will work on smartphones, starting with a prompt to submit a picture of your “skin concern” (examples include moles, birthmarks and rashes), with the visual information then analysed by the AI before being converted into a gallery of suggested conditions.

Google is keen to emphasis the inclusivity of its AI model, stating: “To make sure we’re building for everyone, our model accounts for factors like age, sex, race and skin types – from pale skin that does not tan to brown skin that rarely burns. We developed and fine-tuned our model with de-identified data encompassing around 65,000 images and case data of diagnosed skin conditions, millions of curated skin concern images and thousands of examples of healthy skin – all across different demographics.”

Review New Product Activity and the latest digital health developments across the industry with Innovation in CHC 2021, the latest report from CHC New Products Tracker. For more information, or to order your copy, please contact melissa.lee@NicholasHall.com

European e-Conference report 2021

In this week’s blog, we highlight the key takeaways from our recent European e-Conference and take a closer look at one of the slides from Nicholas Hall’s Global Trends presentation, looking at the fastest-growing brands in consumer healthcare over the past five years.

Nicholas Hall Writes: 100 delegates from around the world joined us in late April for our first-ever e-Conference, and many more are expected to listen to the recording. The conference reviewed global and European trends in the consumer healthcare market, the impact of Covid, changing consumer attitudes and the omnichannel shopper journey, the digital revolution and our forecasts for the future. These and many other topics were covered under the banner of “A Glimpse into the New Normal”.

There is no denying that “immunity” is the biggest buzzword in consumer healthcare at the moment, and has produced some amazing results. We’ve just completed an analysis of the new DB6 data, looking at the fastest-growing brands over the past five years. Just to be clear, this is drawn from the 200 biggest brands and excludes those specifically from China, which are very largely formulated with traditional Chinese medicine. Sambucol, a brand I love dearly and have used for 20 years, shows up as the second fastest growing brand. Only Biofreeze (to be acquired by Reckitt in a deal expected to complete in Q2 2021) has grown faster during this period.

Source: Nicholas Hall’s DB6 database. All values US$mn at MSP.

CHC Insight Europe Editor Sarah Carter and Researcher / Writer Nathalie Corbett filed this report summarising various highlights from our European e-Conference:

  • There is an increased consumer focus on prevention, not just in terms of avoiding Covid-19, but also awareness that people with better overall health have better lifestyle outcomes. Many consumers are no longer looking for treatment, but instead seek to safeguard their future health.
  • During the pandemic, the health consumer has evolved from patient to “consum’actor”, who uses their purchasing power to protect the values and causes they believe in.
  • The consumer is in control of our industry and we need to deliver on their expectations. The best medicine is a consumer who is informed, empowered and inspired.
  • The way consumers shop has been severely disrupted and perhaps irrevocably altered by the pandemic. The CHC industry must respond with agility in order to successfully compete in this omnichannel landscape.
  • Consumers cross these different channels in a way that’s seamless, with lines blurring between communication, point of purchase, advertising, etc.
  • It’s all about the data – get this data culture deeply embedded at all levels of your organisation. It’s also about the right data, and not being inundated with data that isn’t useful. Identify the relevant KPIs and target those.
  • Tech and Big Data can help us gather insights and use these to deliver relevant business developments and product innovations. Consumers themselves are increasingly generating a wealth of data, including via self-monitoring devices.
  • Online can offer opportunities that offline cannot, even when it comes to personal advice. Digital interactions are sometimes preferable vs crowded stores / time constraints.
  • But pharmacies still account for 76% of purchases, and have a superb chance to fight back and regain market share provided they collect new insights into their customers’ shopping journeys.
  • We should no longer refer to e-commerce, but rather e-life. Platforms like Amazon are increasingly media hubs rather than just online stores.
  • Brand building is more important than ever as consumers adapt to the New Normal. We must be present and relevant and focus on creating an emotional bond with the consumer, a traditionally weak area.
  • There can be no return to old strategies and the old way of doing business. It is time for new strategies and New Paradigms.

We hope you enjoyed our European e-Conference 2021! If you couldn’t attend, you can still purchase a recording of the meeting by contacting elizabeth.bernos@NicholasHall.comImmunity & other Growth Drivers will be the focus of our next round of regional hot topic webinars. Starting with a focus on Asia-Pacific on 19 May, on the Americas on 23 June and concluding with Europe on 21 July. Please contact elizabeth.bernos@NicholasHall.com to find out more.

Q1 2021 Results: CCA Round-up

Five of the Top 6 global CHC marketers have now reported their Q1 2021 results, and the clear common theme is a difficult start to the year as a result of the downturn in cough, cold & allergy sales. Global No.1 GSK reported that Consumer Healthcare sales were down 9% as a direct result of the year-on-year “pantry-loading” comparison, including accelerated purchases across all categories driven by the pandemic, combined with a historically weak cold & flu season. GSK’s Respiratory Health portfolio was down 42% in Q1, with Theraflu and Robitussin declining in double-digits, and Contac hit by a high single-digit fall, all adversely impacted by a lower cold & flu season.

Global No.2 J&J reported that Consumer Health worldwide operational sales were down 2.9%, primarily driven by negative prior-year comparisons related to Covid pantry loading in Q1 2020, mainly in OTC products, which declined by 14.8% in Q1 2021 as a result of lower cough, cold & flu incidences. This was partially offset by growth in Listerine mouthwash, Johnson’s baby care products, international skin health / beauty products and Nicorette sales outside the USA.

Sanofi’s Consumer Healthcare sales decreased by 7.3% in Q1 2021, primarily reflecting the weak cough / cold season, as well as a high base for comparison in Q1 2020 and divestments of non-core products. Allergy fell by 6.2%, while Cough & Cold sales were down 59.4% in Q1 2021. This heavy decline was offset by gains for Digestive Wellness (+14.6%), Physical Wellness and Mental Wellness (+18.8%) products. In USA and Rest of the World, growth of the Digestive and Mental Wellness categories partially offset lower Cough / Cold and Pain sales, but in Europe CHC sales fell by 19.3% in Q1.

Reckitt Q1 2021 net revenue was up 4.1% (like-for-like), and e-Commerce was +24%, accounting for 13% of total net revenue, driven by increased investment. Health fell 13.0%, reflecting a volume decline of 14.2% and price / mix improvements of 1.2%, as overall price growth was offset by relatively higher trade investment in North America. The OTC portfolio fell by just under 40%; in addition to challenging comparatives owing to significant pantry-loading in March 2020, this reflects an exceptionally weak cough, cold & flu season – estimated to be around 90% lower than the prior year – resulting in declines for Strepsils, Nurofen and Mucinex.

P&G’s Health Care organic sales were up 3% in Q1 2021, while Personal Health Care organic sales fell by mid-single digits, primarily owing to pandemic-related increases in consumer and retailer inventories in the base period and a weaker than average cough, cold & flu season. Representing 14% of global sales, e-Commerce sales increased by around 50% fiscal year-to-date, with no noticeable change in shopping trends in the quarter. CFO Andre Schulten said in an earnings call that a portion of the impact of commodity cost challenges in the next fiscal year would be offset with price increases in the baby care, feminine care and adult incontinence businesses, which will go into effect in mid-September 2021.

Celine Waller VP, DB6 comments: The poor CHC results reported were set against a robust performance in Q1 2020 when consumers were stockpiling ahead of lockdown restrictions (J&J’s OTC business increased operationally by 25.8% in Q1 2020!) and we expect that they will improve as the year goes on. However, 2021 is expected to be affected by a very weak cough / cold season as lockdowns (still in effect in many markets), social distancing, hygiene measures and mask-wearing continue to suppress incidence of respiratory illnesses, while there are some doubts about whether the high consumption levels of disinfectants and immune-boosting supplements can be sustained. As such, we have lowered our expectations of CHC growth in 2021 to 2.3% in the retail market. However, as highlighted in the P&G results, the 2020 boom in e-Commerce sales is continuing into the current year and we forecast that combined CHC sales in all channels will come out at a respectable 4.0% in 2021.

We are pleased to announce that our annual bestselling report, Nicholas Hall’s CHC Yearbook 2021, is now published digitally! You can analyse key players’ performance, hot topics, global retailing, the Top 15 markets and much more! Print copies will follow soon. For more information, or to order your copy, please contact melissa.lee@NicholasHall.com.